Table 3.
Characteristics of patients who received treatment by 12 months of eligibility and after 12 months of eligibility
| Total treated (n=375) | Treated by 12 months (n=316) | Treated after 12 months (n=59) | p Value | |
|---|---|---|---|---|
| Mean age (years) | 45±13 | 45±13 | 45±12 | 0.85 |
| Male | 61.1% | 61.7% | 57.6% | 0.56 |
| Asian | 96.5% | 96.2% | 98.3% | 0.42 |
| HBeAg-positive | 35.9% | 37.5% | 28.8% | 0.21 |
| Baseline ALT, U/L | 57 (38–96) | 61 (41–104) | 38 (27–52) | <0.00001 |
| Baseline HBV DNA, log10 IU/mL | 5.8 (4.6–7.4) | 5.9 (4.6–7.5) | 5.2 (4.7–7.1) | 0.45 |
| Cirrhosis | 8.8% | 9.8% | 3.4% | 0.11 |
Values are presented as mean±SD, proportions, or median (IQR).
ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV DNA, hepatitis B virus DNA.